Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients

被引:31
作者
Battezzati, PM
Zuin, M
Crosignani, A
Allocca, M
Invernizzi, P
Selmi, C
Villa, E
Podda, M
机构
[1] Univ Milan, Sch Med San Paolo, Osped San Paolo, Dept Med Surg & Dent, I-20143 Milan, Italy
[2] Univ Modena, Dept Internal Med, I-41100 Modena, Italy
关键词
D O I
10.1046/j.1365-2036.2001.01018.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA). Aim: To evaluate the long-term effects of colchicine and UDCA in symptomatic PBC patients. Patients/methods: We extended up to 10 years the double-blind treatment of 44 symptomatic PBC patients originally included in a 3-year multicentre study comparing UDCA and colchicine (U + C) versus UDCA and placebo (U + P). Outcome measures were death or liver transplantation; incidence of clinically relevant events; clinical and quantitative variables retaining prognostic information. Results: Mean follow-up was 7 +/- 3 years. One patient was lost, three withdrew because of jaundice (U + P); two patients stopped colchicine but remained on UDCA. Eleven patients (two for liver-unrelated reasons, U + P) and six patients (U + C) died, three and two patients, respectively, were transplanted (incidence rate difference, five cases per 100 patient-years; 95% CI, -1 to 11). Hepatocellular carcinoma developed in one (U + P) and four (U + C) patients (difference, -2; CI, -5 to 1), portal hypertension complications in nine patients from each group (difference, 1; CI, -5 to 6). Trends of serum bilirubin, Mayo score, antipyrine clearance were similar among treatment groups. Conclusions: In cirrhotic PBC patients, colchicine does not offer additional benefits to UDCA. In this population, UDCA does not obviate disease progression.
引用
收藏
页码:1427 / 1434
页数:8
相关论文
共 27 条
[1]   Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis [J].
Almasio, PL ;
Floreani, A ;
Chiaramonte, M ;
Provenzano, G ;
Battezzati, P ;
Crosignani, A ;
Podda, M ;
Todros, L ;
Rosina, F ;
Saccoccio, G ;
Manenti, F ;
Ballardini, G ;
Bianchi, FP ;
Scheuer, PJ ;
Davies, SE ;
Craxì, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (12) :1645-1652
[2]   URSODEOXYCHOLIC ACID FOR SYMPTOMATIC PRIMARY BILIARY-CIRRHOSIS - PRELIMINARY-ANALYSIS OF A DOUBLE-BLIND MULTICENTER TRIAL [J].
BATTEZZATI, PM ;
PODDA, M ;
BIANCHI, FB ;
NACCARATO, R ;
ORLANDI, F ;
SURRENTI, C ;
PAGLIARO, L ;
MANENTI, F ;
BERTOLINI, E ;
CAMISASCA, M ;
CROSIGNANI, A ;
ZUIN, M ;
FUSCONI, M ;
BALLARDINI, G ;
CASSANI, F ;
ORLANDI, F ;
MACARRI, GP ;
BENEDETTI, A ;
CHIARAMONTE, M ;
FLOREANI, AR ;
POZZI, M ;
BIAGINI, MR ;
ALMASIO, P ;
PROVENZANO, G ;
SCALISI, I ;
BELLENTANI, S ;
TABARRONI, G ;
RODA, A ;
ANNONI, G ;
BISIANI, G .
JOURNAL OF HEPATOLOGY, 1993, 17 (03) :332-338
[3]   EVALUATION OF COLCHICINE THERAPY IN PRIMARY BILIARY-CIRRHOSIS [J].
BODENHEIMER, H ;
SCHAFFNER, F ;
PEZZULLO, J .
GASTROENTEROLOGY, 1988, 95 (01) :124-129
[4]  
COMBES B, 1995, HEPATOLOGY, V22, P759, DOI 10.1016/0270-9139(95)90294-5
[5]   Clinical pharmacokinetics of therapeutic bile acids [J].
Crosignani, A ;
Setchell, KDR ;
Invernizzi, P ;
Larghi, A ;
Rodrigues, CMP ;
Podda, M .
CLINICAL PHARMACOKINETICS, 1996, 30 (05) :333-358
[6]   PROGNOSIS IN PRIMARY BILIARY-CIRRHOSIS - MODEL FOR DECISION-MAKING [J].
DICKSON, ER ;
GRAMBSCH, PM ;
FLEMING, TR ;
FISHER, LD ;
LANGWORTHY, A .
HEPATOLOGY, 1989, 10 (01) :1-7
[7]   Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis [J].
Goulis, J ;
Leandro, G ;
Burroughs, AK .
LANCET, 1999, 354 (9184) :1053-1060
[8]  
GREENBLATT DJ, 1979, INT J CLIN PHARM BI, V17, P401
[9]   Management of primary biliary cirrhosis [J].
Heathcote, EJ .
HEPATOLOGY, 2000, 31 (04) :1005-1013
[10]   Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: A prospective randomized study [J].
Ikeda, T ;
Tozuka, S ;
Noguchi, O ;
Kobayashi, F ;
Sakamoto, S ;
Marumo, F ;
Sato, C .
JOURNAL OF HEPATOLOGY, 1996, 24 (01) :88-94